SeaStar Medical (NASDAQ:ICU) Stock Price Up 1.3% – Still a Buy?

SeaStar Medical Holding Corporation (NASDAQ:ICU)’s share price traded up 1.3% during mid-day trading on Monday . The stock traded as high as $3.08 and last traded at $3.07. 11,203 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 47,014 shares. The stock had previously closed at $3.03.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ICU shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. Wall Street Zen cut shares of SeaStar Medical from a “hold” rating to a “sell” rating in a report on Sunday, August 23rd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.00.

SeaStar Medical Price Performance

The business has a 50 day simple moving average of $3.48 and a 200 day simple moving average of $3.52. The stock has a market cap of $13.36 million, a PE ratio of -0.77 and a beta of -1.05.

SeaStar Medical (NASDAQ:ICU) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.06. The company had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.49 million. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%. As a group, sell-side analysts forecast that SeaStar Medical Holding Corporation will post -3.66 earnings per share for the current fiscal year.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.